Biogen Idec (BIIB)

Biogen Idec (BIIB - Analyst Report) posted solid results in the second quarter of 2009, despite the slowdown in Tysabri sales due to fears of PML. We think the Biogen core business will remain strong over the next several quarters.

Tysabri prescriptions are showing improvement and we believe will resume their previous pace shortly. In the meantime, the name is significantly under-valued and would be a very attractive takeout candidate for a large-cap pharmaceutical company looking for a great phase III pipeline. We expect 2009 to be an eventful year on the pipeline front.

As investors become more comfortable with both Tysabri trends and emerging pipeline, we believe shares will recover back into the low $60's. At today's price, the name is too attractive to ignore.

Biogen Idec (BIIB) : FULL ANALYST REPORT

Email	Print	Share	RSS	Rate Pos	Rate Neg	Comment

Loading Stories...

Related Content

RELATED ARTICLES BULL OF THE DAY ARCHIVE

Zacks Blog: Biogen Beats & Guides Higher
(BIIB, ELN)	02/09/10
Zacks Blog: Company News for February 9, 2010
(BIIB, IFF, TAP, CVH, NYX, VZ, BAC, MON, SAP, RDS, HBC)	02/09/10
Zacks Equity Research: Report For IDPH
N/A	02/04/10
PREMIUM: Zacks Blog: Pharma & Biotech Stock Review
(RX, ABT, JNJ, PFE, MRK, BMY, SNY, MYL, GSK, ACL, GILD, BIIB, ACOR)	01/28/10
PREMIUM: Zacks Analyst Interviews: Pharma & Biotech Stock Review
(BIIB)	01/28/10

 Posting Comment...

There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]

Comments (Limit 1000 Characters - Used: 0)

Please provide your comments here... Display Name: Email Address:  

 Loading Comments...

Be the first to comment on this article!